home / stock / cyccp / cyccp news

CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 11/11/20

Stock Information
Company Name: Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock
Stock Symbol: CYCCP
Market: NASDAQ
Website: cyclacel.com
Menu
CYCCP CYCCP Quote CYCCP Short CYCCP News CYCCP Articles CYCCP Message Board
Get CYCCP Alerts

News, Short Squeeze, Breakout and More Instantly...
CYCCP - Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Opera...
CYCCP - Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third q...

CYCCP - Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on&...

CYCCP - Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced clinical data demonstrating safety, anti-tum...
CYCCP - Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M....

CYCCP - Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to parti...

CYCCP - Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data...
CYCCP - Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2020 Earnings Conference Call August 12, 2020 16:30 ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Offi...

CYCCP - Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second ...

CYCCP - Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results ...
Previous 10 Next 10